CAR-T Therapy: Safety, Efficacy, and Immune-Escape Mechanisms

The study is a biological, drug-related, non-interventional observational study with both retrospective and prospective components. No experimental diagnostic procedures, investigational medicinal products, or medical devices will be used, and samples will be collected as part of routine clinical practice.

Inclusion Criteria: To achieve the objectives of this study, biological samples will be obtained from patients aged 18 years or older who meet at least one of the following inclusion criteria: * Patients eligible for CAR-T-cell therapy who have signed at least an initial informed consent for evaluation for this treatment at our center. * Patients who have previously signed the informed consent for the Hematological Malignancies Biobank (Biobanca Neoplasie Ematologiche) and for whom stored biological samples are available. * Patients eligible for bispecific antibody therapy who have signed at least an initial informed consent for evaluation for this treatment at our center. Exclusion Criteria: * Participation in clinical trial protocols that explicitly prohibit participation in biological observational studies.